肿瘤高危患儿是指发生肿瘤概率高于一般人群的患儿。目前认为，这类患儿如果合并生长激素缺乏症，可以谨慎使用生长激素治疗。
这是因为生长激素并没有致癌作用，不会进一步增加肿瘤高危患儿的肿瘤风险。更何况生长激素缺乏症采用生理剂量进行治疗，风险就更加小了。
参考文献：
Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, Hoffman AR, Polak M, Yuen KCJ, Alos N, Antal Z, Bidlingmaier M, Biller BMK, Brabant G, Choong CSY, Cianfarani S, Clayton PE, Coutant R, Cardoso-Demartini AA, Fernandez A, Grimberg A, Guðmundsson K, Guevara-Aguirre J, Ho KKY, Horikawa R, Isidori AM, Jørgensen JOL, Kamenicky P, Karavitaki N, Kopchick JJ, Lodish M, Luo X, McCormack AI, Meacham L, Melmed S, Mostoufi Moab S, Müller HL, Neggers SJCMM, Aguiar Oliveira MH, Ozono K, Pennisi PA, Popovic V, Radovick S, Savendahl L, Touraine P, van Santen HM, Johannsson G. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol. 2022:P35-P52. DOI:10.1530/eje-21-1186. PMID: 35319491.